Add Formweb to your mobile device
Search results for:
ravulizumab
ravulizumab
Last updated: Apr. 28, 2026
- Black Box Warning: Serious Meningococcal Infections
- REMS: Ultomiris and Soliris-FDA FEMS Info
- REMS: Legacy Health REMS Requirements-Ravulizumab
- Restricted Restricted Medication
This medication is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader.
See HERE for more information and workflow.
See HERE for additional pharmacy workflow details.
The goal of the Ultomiris and Soliris, and the Epysqli REMS programs are to mitigate the risk of serious meningococcal infections, and includes health care provider, patient, health care setting/pharmacy and wholesaler-distributor requirements for dispensing.
See Legacy Health REMS Requirements for detail.